An article in Lancet Neurology shed fresh light, appreciated by investors, on GW Pharma plc's Epidiolex, a purified form of cannabidiol (CBD), in the works for two orphan drug indications, Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), genetic forms of epilepsy that are resistant to existing drugs.